Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2021 | Identification of genetic markers associated with ibrutinib-related cardiovascular toxicity

Nilanjan Ghosh • 24 Jun 2021
ASCO 2021 EHA 2021
Chronic Lymphocytic Leukemia Leukemia Ibrutinib

Nilanjan Ghosh MD, PhD, Levine Cancer Institute, Charlotte, NC, discusses the identification of polymorphisms in genes of the Bruton’s Tyrosine Kinase (BTK) signaling pathway associated with ibrutinib-related cardiovascular side effects (CVSEs) observed in patients with chronic lymphocytic leukemia (CLL). In patients with CLL treated with ibrutinib monotherapy, five single nucleotide polymorphisms (SNPs) were significantly associated with CVSEs: GATA4, SGK1, KCNQ1, NPPA and SCN5A. A genetic risk score indicated increased risk of CVSEs in patients with at least two SNPs. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Nilanjan Ghosh

Long-term follow-up results of Mosun-Pola versus R-Pola in patients with R/R LBCL
6:42
Long-term follow-up results of Mosun-Pola versus R-Pola in patients with R/R LBCL
Nilanjan Ghosh • 10 Dec 2025
Evaluation of real-world venetoclax initiation prophylaxis & monitoring outcomes in CLL
2:31
Evaluation of real-world venetoclax initiation prophylaxis & monitoring outcomes in CLL
Nilanjan Ghosh • 10 Dec 2025
Key takeaways & trials from ICML in DLBCL, MCL, and FL: POLARGO, STARGLO, MorningSun & more
15:00
Key takeaways & trials from ICML in DLBCL, MCL, and FL: POLARGO, STARGLO, MorningSun & more
Nilanjan Ghosh • 27 Jun 2025
An overview of CAR T-cell therapies in the treatment of patients with MCL
6:46
An overview of CAR T-cell therapies in the treatment of patients with MCL
Nilanjan Ghosh • 26 Jun 2024

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals